Abstract
Two children, ages 13 2/12 and 2 6/12 years, with osteogenesis imperfecta were treated with salmon calcitonin. During the course of therapy the older child developed calcitonin dose-related hypomagnesemia on two occasions. The younger child, coincident with otitis media and vomiting, developed hypomagnesemia, hypophosphatemia, hyponatremia, and hypokalemia. Since rib biopsies obtained before and after one year of treatment with salmon calcitonin failed to demonstrate any histologic changes, therapy was discontinued because of the induced metabolic consequences of calcitonin therapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1001-1005 |
| Number of pages | 5 |
| Journal | Journal of Pediatrics |
| Volume | 91 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1977 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Cite this
Calcitonin therapy of children with osteogenesis imperfecta. / August, Gilbert P.; Shapiro, Jay; Hung, Wellington.
In: Journal of Pediatrics, Vol. 91, No. 6, 1977, p. 1001-1005.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Calcitonin therapy of children with osteogenesis imperfecta
AU - August, Gilbert P.
AU - Shapiro, Jay
AU - Hung, Wellington
PY - 1977
Y1 - 1977
N2 - Two children, ages 13 2/12 and 2 6/12 years, with osteogenesis imperfecta were treated with salmon calcitonin. During the course of therapy the older child developed calcitonin dose-related hypomagnesemia on two occasions. The younger child, coincident with otitis media and vomiting, developed hypomagnesemia, hypophosphatemia, hyponatremia, and hypokalemia. Since rib biopsies obtained before and after one year of treatment with salmon calcitonin failed to demonstrate any histologic changes, therapy was discontinued because of the induced metabolic consequences of calcitonin therapy.
AB - Two children, ages 13 2/12 and 2 6/12 years, with osteogenesis imperfecta were treated with salmon calcitonin. During the course of therapy the older child developed calcitonin dose-related hypomagnesemia on two occasions. The younger child, coincident with otitis media and vomiting, developed hypomagnesemia, hypophosphatemia, hyponatremia, and hypokalemia. Since rib biopsies obtained before and after one year of treatment with salmon calcitonin failed to demonstrate any histologic changes, therapy was discontinued because of the induced metabolic consequences of calcitonin therapy.
UR - http://www.scopus.com/inward/record.url?scp=0017662644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017662644&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(77)80916-5
DO - 10.1016/S0022-3476(77)80916-5
M3 - Article
C2 - 562930
AN - SCOPUS:0017662644
VL - 91
SP - 1001
EP - 1005
JO - Journal of Pediatrics
JF - Journal of Pediatrics
SN - 0022-3476
IS - 6
ER -